Blood cancer, Acute myeloid leukemia, Cancer
KURAKura OncologyCatalyst overview
Research summary
This catalyst tracks a Phase 1b data readout for Ziftomenib + venetoclax/azacitidine (ven/aza) or cytarabine/daunorubicin (7+3) in Blood cancer, Acute myeloid leukemia, Cancer. The expected timing is based on the latest available company guidance and may change.
KOMET-007 trial. 1/30/24- Initial data from 20 patients. Enrollment at 400 mg dose ongoing. 12/9/24- Interim data reported and presented at ASH '24. 2/26/25- Present prelim data at a medical meeting in Q2 2025. 5/14/25- Present Ph1a/b results at EHA on June 12-15, 2025. 6/12/25- Reported positive updated combination data. 10/1/25- Ph1b initiated. 11/04/25:- ASH 2025 oral ven/aza data planned in December 2025 for KOMET-007. 12/08/25:- ASH 2025 KOMET-007 Phase 1a/1b triplet data showed high responses and tolerable safety in NPM1-mutated and KMT2A-rearranged AML. 01/11/26:- Plan updated KOMET-007 7+3 cohort data in H1 2026; quad 7+3 plus quizartinib cohort enrollment advancing. 03/05/26:- First patient dosed in KOMET-007 quizartinib+7+3 FLT3-ITD cohort; updated 7+3 frontline data planned in H1 2026. 05/12/26:- EHA oral KOMET-007 7+3 updated 99-pt data on June 14, 2026. High CRc and MRD negativity reported. 05/12/26:- EHA 2026 oral KOMET-007 7+3 frontline AML updated data in June 2026 reiterated; strong CRc and MRD. 06/11/26:- KOMET-007 7+3 long-term results reported; 12-month survival 94% in NPM1-mutated AML. Publication planned H2 2026. 08/12/26:- KOMET-007 7+3 long-term data reported. Initial quizartinib plus 7+3 data and updated ven/aza data are expected in H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.